25,145 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Abacus FCF Advisors LLC

Abacus FCF Advisors LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 25,145 shares of the company's stock, valued at approximately $608,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. lifted its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in Hims & Hers Health during the 4th quarter worth approximately $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the transaction, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 36,460 shares of the business's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the sale, the chief executive officer now owns 27,918 shares of the company's stock, valued at $756,298.62. The trade was a 56.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 824,303 shares of company stock valued at $31,376,661 over the last three months. 17.71% of the stock is currently owned by insiders.

Remove Ads

Hims & Hers Health Stock Performance

Shares of HIMS stock traded up $0.48 during trading on Monday, hitting $27.71. 7,407,316 shares of the company were exchanged, compared to its average volume of 15,116,924. The business's 50-day simple moving average is $38.75 and its 200 day simple moving average is $30.46. The firm has a market capitalization of $6.16 billion, a price-to-earnings ratio of 62.98 and a beta of 1.65. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent analyst reports. Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Truist Financial cut their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday. Bank of America boosted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Finally, Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $38.25.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.